The Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

南京三寶科技股份有限公司
NANJING SAMPLE TECHNOLOGY CO.,LTD.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1708)

RE-DESIGNATION OF DIRECTOR CHANGES IN CHAIRMAN, CHIEF EXECUTIVE OFFICER AND COMPOSITION OF THE STRATEGY COMMITTEE

The board of directors (the "**Board**") of Nanjing Sample Technology Co., Limited* (the "**Company**") hereby announces that:

(1) due to Mr. Sha Min ("**Mr. Sha**") not having sufficient time to participate in the daily management of the Company, Mr. Sha has been re-designated from an executive director to a non-executive director of the Company. At the same time, Mr. Sha has been relieved of his positions as the chairman of the Board, the chief executive officer of the Company, and the member and chairman of the strategy committee of the Board.

(2) in order to fill the vacancies of the positions of the chairman of the Board, the chief executive officer of the Company, and the member and chairman of the strategy committee of the Board, and taking into account the actual operational needs of the Company, Mr. Liu Fei ("**Mr. Liu**"), a non-executive director of the Company, has been re-designated as an executive director of the Company. At the same time, Mr. Liu has been appointed as the chairman of the Board, the chief executive officer of the Company, and the member and chairman of the strategy committee of the Board.

The above re-designation, removal and appointment have taken effect from 10 November 2025 until the expiry of the term of the ninth session of the Board on 31 December 2027.

Set out below are the biographical details of Mr. Sha:

Mr. Sha Min (沙敏), aged 60, graduated from Southeast University (東南大學) with a master's degree, is a senior engineer and a senior economist. Mr. Sha joined the Company in December 1997 and currently serves as a director of the Company's subsidiaries, namely Nanjing Sample Logistic Company Ltd.* (南京三寶物流科技有限公司). He is also the vice chairman and general manager of Nanjing Sample Technology Group Co., Ltd.* (南京三寶科技集團有限公司) ("**Sample Group**"), the controlling shareholder of the Company. He holds positions in certain subsidiaries of Sample Group, including a director of Nanjing Tongrentang Health Pharmaceutical Group Co., Ltd.* (南京同仁堂健康藥業集團有限公司), an executive director and general manager of Nanjing Sample Corporate Development Co., Ltd.* (南京三寶企業發展有限公司), the chairman of Jiangsu Cross-border e-Commerce Services Co., Ltd.* (江蘇跨境電子商務服務有限公司), Zhong Jian Zhi Kang Supply Chain Service Company Ltd.* (中健之康供應鏈服務有限責任公司), the vice chairman of Nanjing Wuzhou Refrigeration Group Co., Ltd.* (南京五洲製冷集團有限公司) and Xinyirun Supply Chain Management (Shanghai) Co., Ltd.* (鑫一潤供應鏈管理(上海)有限公司). In addition, Mr. Sha served as a non-executive director of Jiangsu NandaSoft Technology Company Limited* (江蘇南大蘇富特科技股份有限公司) (a company previously listed on the Hong Kong Stock Exchange, Hong Kong stock code: 8045) during the period from November 2017 to May 2025, he is currently the vice chairman of Nanjing Turbine Motor (Group) Co., Ltd.* (南京汽輪電機(集團)有限責任公司), the chairman and general manager of Jiangsu Century Express Technology Co., Ltd.* (江蘇世紀運通科技有限公司), an executive director and general manager of Jiangsu Sample Holding Group Ltd.* (江蘇三寶控股集團有限公司) ("**Jiangsu Sample**").

Mr. Sha has entered into a service agreement with the Company for a term of three years commencing from 1 January 2025 subject to the retirement and re-election requirements of the articles of association of the Company. The emoluments of Mr. Sha will be determined by the Company with reference to the basis of prevailing market conditions and his roles and responsibilities. As at the date of the announcement, Mr. Sha is entitled to a director's fee of RMB55,000 (including tax) per annum, and he has waived the right to receive any salary and allowance from the Company.

Set out below are the biographical details of Mr. Liu:

Mr. Liu Fei (劉飛), aged 43, graduated from Shantou University (汕頭大學) with a postgraduate degree in business administration. Mr. Liu held positions as board secretary and vice president of the group at Shantou Dongfeng Printing Co., Ltd.* (汕頭東風印刷股份有限公司) (now renamed Guangdong DFP New Material Group Co., Ltd.* (廣東東峰新材料集團股份有限公司), a company listed on the main board of the Shanghai Stock Exchange with stock code 601515) from July 2004 to June 2020. From July 2020 to November 2021, he worked at Shandong Fengyuan Chemical Co., Ltd.* (山東豐元化學股份有限公司) (a company listed on the main board of the Shenzhen Stock Exchange with stock code 002805) as a director, deputy general manager and board secretary. Since December 2021, he has been serving as deputy director of capital operation center at Qingdao Haifa State Owned Capital Investment and Operation Group Co., Ltd.* (青島海發國有資本投資運營集團有限公司), a parent company of the Company's controlling shareholder, Sample Group.

Mr. Liu currently serves as a director of Sample Group and holds positions in the several subsidiaries of Sample Group, including a director of Nanjing Tongrentang Health Pharmaceutical Group Co., Ltd.* (南京同仁堂健康藥業集團有限公司), Nanjing Tongrentang Pharmaceutical Co., Ltd.* (南京同仁堂藥業有限責任公司), Nanjing Tongrentang Medical Marketing Co., Ltd.* (南京同仁堂醫藥營銷有限公司), Nanjing Tongrentang Liuhe Qiankun Health Development Co., Ltd.* (南京同仁堂六和乾坤健康發展有限公司), Nanjing Tongrentang Lejia Laopu Investment Co., Ltd.* (南京同仁堂樂家老鋪投資股份有限公司) and Qingdao Big Data Technology Development Co., Ltd.* (青島大數據科技發展有限公司). He also holds the position of chairman of Nanjing Tongrentang Kangpu Biotechnology Co., Ltd.* (南京同仁堂康普生物技術有限公司), Qingdao Baohao Technology Co., Ltd.* (青島寶昊科技有限公司) and Nanjing Lianhua Tang Health Technology Co., Ltd.* (南京市蓮華堂健康科技有限公司) as well as the chairman and general manager of Nanjing Tongrentang Health Industry Co., Ltd.* (南京同仁堂健康產業有限公司). Mr. Liu was appointed as a non-executive director of the Company on 30 September 2024.

Mr. Liu has entered into a service agreement with the Company for a term of three years commencing from 1 January 2025 subject to the retirement and re-election requirements of the articles of association of the Company. Mr. Liu's emolument will be determined by the Company with reference to the prevailing market conditions, his duties and his responsibilities. As of the date of this announcement, Mr. Liu is entitled to a director's fee of RMB55,000 (including tax) per annum, and he has waived the right to receive any salary and allowance as well as the director's fee from the Company.

Other Information:

As at the date of this announcement, Mr. Sha directly holds 3,375,000 domestic shares of the Company and is indirectly interested in 60.40% of equity interest of Jiangsu Sample which in turn owns 49% of the equity interest in Sample Group. Sample Group directly holds 397,821,000 domestic shares of the Company, representing approximately 50.22% of the issued share capital of the Company and owns indirectly 4,310,000 H shares of the Company, representing approximately 0.54% of the issued share capital of the Company. Sample Group is owned as to 49% by Jiangsu Sample which in turn is held as to 60.40% by Shanghai Jiaxin Enterprise Management Center (limited partnership)* (上海佳鑫企業管理中心有限合夥) ("**Shanghai Jiaxin**") which in turn is beneficially owned as to 100% by Mr. Sha. Under the SFO, Mr. Sha is deemed to be interested in the entire equity interest in each of Sample Group, Jiangsu Sample and Shanghai Jiaxin, therefore, Mr. Sha is deemed to be interested in all 401,196,000 domestic shares of the Company and 4,310,000 H shares of the Company.

Save as disclosed above, as at the date of this announcement, each of Mr. Sha and Mr. Liu does not (i) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Hong Kong Laws); (ii) have any relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; (iii) hold any other positions with the Company or other members of the the Company and its subsidiaries; and (iv) hold any directorships in any other listed companies in the last three years.

Save as disclosed above, there are no other matters relating to the proposed appointments of each of Mr. Sha and Mr. Liu that need to be brought to the attention of the shareholders of the Company and there is no information which requires to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Pursuant to code provision C.2.1 of the Corporate Governance Code (the "**CG Code**") in Appendix C1 to the Listing Rules, the roles of chairman and chief executive should be separated and should not be performed by the same individual. Mr. Sha Min has served as the chairman of the Board and chief executive officer of the Company since 3 March 2023. Following the appointment of Mr. Liu as the chairman of the Board and chief executive officer of the Company, Mr. Liu will assume dual roles of the chairman of the Board and the chief executive officer of the Company. After evaluation of the current situation of the Company and taking into account of the experience and past performance of Mr. Liu, the Board is of the opinion that it is appropriate at the present stage for Mr. Liu to hold both positions as the chairman of the Board and the chief executive officer of the Company as it ensures the stability of the operations of the Company with consistent leadership and policy formulation, which is conducive to the efficiency of the Company's overall strategic planning and business decision-making and implementation. In addition, the remaining two executive directors have also been appointed as vice president of the Company to assist Mr. Liu in overseeing the business operation and management. Therefore, the Directors believe that the layout of this management structure will be more beneficial to the future development of the Company and can improve the Company's operating conditions. Under the supervision of the Board (currently composed of three executive Directors, one non-executive Director and three independent non-executive Directors), the Board is appropriately structured with balance of power to provide sufficient checks to protect the interests of the Company and its shareholders. Therefore, the Board considers the deviation from code provision C.2.1 of the CG Code is appropriate under such circumstances.

By Order of the Board
Nanjing Sample Technology Company Limited*
Liu Fei
Chairman

Nanjing, the PRC
10 November 2025

As at the date hereof, the executive Directors are Mr. Liu Fei (Chairman), Mr. Ma Fengkui and Mr. Liu Min, the non-executive Director is Mr. Sha Min; and the independent non-executive Directors are Mr. Hu Hanhui, Mr. Gao Lihui and Ms. Chung Yuet Mei.

* *For identification purpose only*